Applied Therapeutics (APLT) Stock Statistics & Valuation Metrics

Applied Therapeutics has a market cap or net worth of $58.05M. The enterprise value is $37.29M.

Applied Therapeutics has 141,575,530 shares outstanding. The number of shares has decreased by -2.65% in one year.

Applied Therapeutics’s return on equity (ROE) is -1.85 and return on invested capital (ROIC) is -173.23%.

The current PE Ratio of Applied Therapeutics is -1.13. Applied Therapeutics’s PEG ratio is -0.08.

In the last 12 months, Applied Therapeutics had revenue of 455.00K and earned -105.62M in profits. Earnings per share was -0.76.

In the last 12 months, operating cash flow was -94.03M and capital expenditures 0.00, giving a free cash flow of -94.03M billion.

Applied Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Applied Therapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.

Applied Therapeutics as a current ratio of 3.06, with Debt / Equity ratio of 7.36%

In the past 12 months, Applied Therapeutics has paid 0.00 in taxes.

Applied Therapeutics EV to EBITDA ratio is -0.41, with an EV/FCF ratio of -0.51.

Applied Therapeutics has $50.76M in cash and marketable securities with $2.70M in debt, giving a net cash position of -$48.06M billion.

Gross margin is 24.15%, with operating margin of -22922.86%, and net profit margin of -23214.07%.

The average price target for Applied Therapeutics is $2.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy